Eli Lilly has unveiled plans to expand its long-standing partnership with Purdue University, with the drugmaker investing up ...

The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

US biotech PTC Therapeutics released mixed new data on its Phase II trial of PCT187 (votoplam) in Huntington’s disease. UK ...

Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and ...

“You have to find community, you have to rely on each other,” says Oscar-nominated actress Lily Gladstone (Killers Of The Flower Moon). She plays Lee in The Wedding Banquet, a reimagining of ...

Eli Lilly and Co. and Purdue University on Friday announced an expanded collaboration agreement, with the Indianapolis drugmaker planning to invest up to $250 million over the next eight years to ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company (LLY)’s share was ...

Under the terms of the agreement, Alchemab will be taking the programme through early phase 1 clinical trials after which Lilly will lead all further development and commercialisation. Alchemab’s ...

New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism – ATLX-1282 is the first programme out of ...